TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05654831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC5004
Description: ECC5004 will be administered as oral tablet(s) during each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC5004
Description: ECC5004 will be administered as oral tablet(s) during each dosing day.
Study: NCT04913129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 8 week home-based exercise therapy 4-5 times/week
Study: NCT04955561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Air
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Air
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Air
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10L/min O2
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10L/min O2
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10L/min O2
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
Study: NCT06123234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum
Description: Food supplement in single-dose vials

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Food supplement in single-dose vials
Study: NCT04642157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELIOS
Description: ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~* A systematic initial contact with an ELIOS web-clinician~* Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~* The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician

Intervention type: OTHER
Group type: OTHER
Intervention: other resources contacts
Description: Three types of resources will be suggested via the ELIOS website:~* The General Practitioner (GP)~* The closest medico-psychologic center (CMP)~* The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation.
Study: NCT04690010

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory tubeless PCNL
Description: Patients will be discharged the same day of surgery. No nephrostomy tube will be left in place. A ureteral stent on a string may be left for up to 5 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient PCNL with nephrostomy tube
Description: Patients will be admitted to hospital for 1-3 days. A nephrostomy tube will be placed at the time of surgery that will be removed prior to discharge.
Study: NCT06405464

Intervention type: DRUG
Intervention: VOCABRIA 30Mg Tablet
Description: CAB 30 mg Film-coated tablets

Intervention type: DRUG
Intervention: EDURANT 25Mg Tablet
Description: RPV 25 mg film-coated tablets

Intervention type: DRUG
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA 600 mg prolonged release suspension for injection (3 mL)

Intervention type: DRUG
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA 900 mg prolonged release suspension for injection (3 mL)

Intervention type: BIOLOGICAL
Intervention: Intact proviral DNA assay
Description: HIV-1 latent reservoir size

Intervention type: BIOLOGICAL
Intervention: Intact proviral DNA assay
Description: HIV-1 latent reservoir size

Intervention type: BIOLOGICAL
Intervention: Full-length sequencing
Description: Proviral DNA

Intervention type: BIOLOGICAL
Intervention: Full-length sequencing
Description: Proviral DNA
Study: NCT04736654

Intervention type: OTHER
Intervention: Survey study
Description: Headache Disability Questionnaire (HDQ) will be applied.
Study: NCT06507163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The post-surgical breathing exercise group
Description: Individuals in the Intervention-1 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for 5 days in the postoperative period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The pre- and post- surgical breathing exercise group
Description: Individuals in the Intervention-2 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for a total of 10 days, 5 days in the preoperative period and 5 days in the postoperative period.
Study: NCT05688787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Injection
Description: .injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest\&amp; T10 cross over iliac crest at a distance 8-10cm
Study: NCT05468073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Description: Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
Study: NCT06095739

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DA-OTC-002
Description: The topical formula of DA-OTC-002 was formed from 2 molecules: an alpha 1 agonist (synephrine) and a TAAR receptor agonist~A 1mL topical application of DA-OTC-002 was applied to a 10cm x 10xm target area of the right side of the scalp of each subject
Study: NCT06071858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: * The study staff clinician will review all medical issues for each patient and reach out to primary care providers (PCP), dieticians, and other medical providers as needed.~* The study staff clinician will serve as point person for communication with emergency departments and inpatient providers if the patient requires those levels of care.~* The clinician will communicate with outside providers to provide background and ensure health decision making by those providers, visit and support patients as appropriate, access outside records and share with rest of the care team, and most critically ensure that a proper discharge plan has been made for the patient including care appointments, access to prescriptions and any new referrals made during hospitalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Peer Support
Description: • Patients will be offered weekly 1:1 sessions with a Peer Provider as part of routine care in a mixture of in-person and virtual formats as appropriate to support patients around treatment decisions, and recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Outreach
Description: • mindLAMP smartphone application for various kinds of outreach including but not limited to medication and/or appointment reminders, resources, and activities such as breathing and meditation exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: * For participants identified as needing and/or wanting support around cognition.~* The cognitive remediation program is available online or in-app and offers memory, attention, processing speed, executive functioning, and social cognition training activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Family Group Therapy
Description: * Families whose loved ones are in CSC clinic will be offered weekly group sessions with a study staff clinician.~* Each group may include 5-8 families and include a mixture of in-person and virtual formats.~* These groups will be open-ended, including psychoeducation, and practical problem-solving discussions around care and other topics.
Study: NCT05241327

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: Inorganic Nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: Inorganic Nitrate
Study: NCT06025435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAIA-HIV-SSP
Description: The Systems Analysis and Improvement Approach (SAIA) is an evidence-based, multicomponent implementation strategy for improving the delivery of appropriate clinical services for HIV prevention and treatment. It involves five cyclical steps including (1) analyzing service delivery data to identify priority areas for system improvements, (2) mapping processes and building consensus around programmatic modifications to address priority areas, (3) implementing programmatic modifications, (4) assessing effects of programmatic modifications on improving delivery of services across the cascade, and (5) repeating steps 1-4 as needed.
Study: NCT06500247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpicilib
Description: This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with dalpicilib until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study: NCT06500247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (II)
Description: This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with Abiraterone Acetate (II) until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Prednisone until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study: NCT05642910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azvudine
Description: Patients received Azvudine orally, for 7 consecutive days (7 doses in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxlovid group
Description: Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
Study: NCT05519345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant Conditioning
Description: Active encouragement and feedback to increase motor evoked response during stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Absence of active encouragement and feedback to increase motor evoked response when stimulated.
Study: NCT06771245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYH9056
Description: PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH9056
Description: PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYH9056
Description: PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYH9056
Description: PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan
Study: NCT05833672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terelizumab
Description: q3w Terelizumab 200mg on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
Study: NCT06538701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterolateral advancement pharyngoplasty
Description: Starting with bilateral tonsillectomy, The palatopharyngeal muscle (PPM) raised and advanced to be fixed to the pterygomandibular raphe, The posterior part of the PPM, together with its attached mucosa, was then advanced superolaterally behind the palatoglossus muscle to be hooked up to the levator veli palatini muscle
Study: NCT06530979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored nutritional education program utilizing Saudi-sign language supplied by Saudi-sign language interpreter
Description: The program will be implemented in an experimental group composed of profoundly impaired hearing adults (91 Decibels and above). The experimental group will receive nutrition group counselling via photos, and models, and Saudi-sign language interpreter, including awareness of food groups and their nutrients, choose healthy and balanced items from supermarkets, restaurants or coffee shop menus-traffic lights on nutrition labelling and health problems or diseases related to diet and weight management
Study: NCT06533995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visuprime
Description: Visuprime is a medical device (class IIa sterile) with ophtalmic indication, consisting on a 10 ml multidose bottle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo eyedrop isotonic buffered saline solution
Study: NCT06771245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamlodipine
Description: 2.5mg PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine
Description: 2.5mg PO once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 80mg PO once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 80mg PO once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYH9056 placebo
Description: PO once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYH9056 placebo
Description: PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine placebo
Description: PO once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan placebo
Description: PO once daily
Study: NCT05426499

Intervention type: DRUG
Intervention: Patients requiring cefotaxime treatment
Description: Dosage according to SmPC

Intervention type: DRUG
Intervention: Patients requiring meropenem treatment
Description: Dosage according to SmPC

Intervention type: DRUG
Intervention: Patients requiring fluconazole treatment
Description: Dosage according to SmPC

Intervention type: DRUG
Intervention: Patients requiring isavuconazole treatment
Description: Dosage according to SmPC
Study: NCT04750538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim 120
Description: 120 BreEStim stimuli will applied for about 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim 120
Description: 120 BreEStim stimuli will applied for about 10 minutes.
Study: NCT05426499

Intervention type: DRUG
Intervention: Patients requiring anidulafungin treatment
Description: Dosage according to SmPC
Study: NCT04750538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim 240
Description: 240 BreEStim stimuli will applied for about 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim 240
Description: 240 BreEStim stimuli will applied for about 20 minutes.
Study: NCT05624463

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified intubation protocol
Description: 1. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified intubation protocol
Description: 1. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional intubation protocol
Description: 1. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional intubation protocol
Description: 1. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early resumption of oral intake
Description: Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early resumption of oral intake
Description: Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed resumption of oral intake
Description: Patients will resume drinking water 6h after the operation at ward. Before patients resume oral drinking, they will be provided 10ml/kg 5% glucose saline intravenously.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed resumption of oral intake
Description: Patients will resume drinking water 6h after the operation at ward. Before patients resume oral drinking, they will be provided 10ml/kg 5% glucose saline intravenously.
Study: NCT05562154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Ankle Replacement
Description: Participants will undergo either lateral approach or anterior approach when having a total ankle replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Ankle Replacement
Description: Participants will undergo either lateral approach or anterior approach when having a total ankle replacement
Study: NCT06152822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib+capecitabine+bevacizumab
Description: pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w
Study: NCT06471582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificially Sweetened Carbohydrate Beverage
Description: Beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose and artificial sweetener

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Artificially Sweetened Beverage
Description: Beverage containing no carbohydrates or kilocalories and an artificial sweetener
Study: NCT05160935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken.